公司概覽
業務類別 Biotechnology
業務概覽 Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
公司地址 350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
電話號碼 +1 650 624-3000
傳真號碼 +1 650 624-3010
公司網頁 https://www.cytokinetics.com
員工數量 673
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. Jeffrey J. Hessekiel Executive Vice President, Chief Legal and Administrative Officer -- 14/11/2025
Dr. Fady Ibraham Malik, M.D.,PhD Executive Vice President, Research and Development 美元 609.46K 10/04/2025
Mr. Robert I. Blum Director, President and Chief Executive Officer 美元 825.55K 26/02/2026
Mr. Sung H. Lee Executive Vice President, Chief Financial Officer and Principal Accounting Officer 美元 550.00K 26/02/2026
Mr. Andrew M. Callos Executive Vice President and Chief Commercial Officer 美元 562.91K 10/04/2025
 
董事會成員
董事會 職務 更新日期
Dr. Robert A. Harrington, M.D. Independent Director 26/02/2026
Mr. James M. Daly Independent Director 26/02/2026
Dr. John T. Henderson, M.B. Chairman of the Board 26/02/2026
Ms. Nancy J. Wysenski Independent Director 26/02/2026
Dr. Edward M. Kaye, M.D. Independent Director 26/02/2026
Dr. Wendell D. Wierenga,PhD Independent Director 26/02/2026
Mr. Robert I. Blum Director, President and Chief Executive Officer 26/02/2026
Ms. B. Lynne Parshall, Esq.,J.D. Independent Director 26/02/2026
Ms. Muna Bhanji, Ph. Independent Director 26/02/2026
Mr. Robert E. Landry Independent Director 26/02/2026
 
所屬ETF (更新日期: 07/03/2026 02:31)
代號 名稱 佔比% 持有日期
NUSCNuveen ESG Small-Cap ETF0.09%27/02/2026
IWOiShares Russell 2000 Growth ETF0.09%28/02/2026
MDYGState Street® SPDR® S&P 400™ Md Cp GrETF0.08%27/02/2026
MDYVState Street® SPDR® S&P 400™ Md CpValETF0.07%27/02/2026
VTVanguard Total World Stock ETF0.07%31/01/2026
RVTRoyce Small-Cap Trust0.06%31/12/2025
VTWVVanguard Russell 2000 Value ETF0.06%31/01/2026
SCHBSchwab US Broad Market ETF™0.06%28/02/2026
FNXFirst Trust Mid Cap Core AlphaDEX® ETF0.06%26/02/2026
LABUDirexion Daily S&P Biotech Bull 3X ETF0.05%26/02/2026
THQabrdn Healthcare Opportunities0.05%31/01/2026
SMLFiShares U.S. Small-Cap Eq Fac ETF0.05%28/02/2026
IVOGVanguard S&P Mid-Cap 400 Growth ETF0.05%31/01/2026
ESMLiShares ESG Aware MSCI USA Small-Cap ETF0.05%28/02/2026
FNYFirst Trust Mid Cap Growth AlphaDEX® ETF0.05%26/02/2026
IUSGiShares Core S&P US Growth ETF0.04%28/02/2026
FHLCFidelity MSCI Health Care ETF0.04%28/02/2026
BBMCJPMorgan BetaBuilders US Mid Cap Eq ETF0.04%27/02/2026
JSMLJanus Henderson Small Cap Gr Alpha ETF0.04%27/02/2026
IUSViShares Core S&P US Value ETF0.04%28/02/2026
  1   2    3    4    5    6  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.